Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Lupin gets USFDA nod for generic version of Levoxyl tablets to treat hypothyroidism

      Lupin gets USFDA nod for generic version of Levoxyl tablets to treat hypothyroidism

      Medical Dialogues Bureau2 Nov 2019 10:00 AM IST
      The product is a generic version of King Pharmaceuticals Research and Development LLC's Levoxyl tablets in same strengths, Lupin said.New Delhi: Drug...
      Alkem Labs closes USFDA inspection of Baddi, Daman facility with 2 observations

      Alkem Labs closes USFDA inspection of Baddi, Daman facility with 2 observations

      Medical Dialogues Bureau2 Nov 2019 9:45 AM IST
      New Delhi: Drugmaker Alkem Laboratories (Alkem Labs) recently informed that the company has received 2 observations from the US health regulator for...
      Tests indicate heartburn drug Zantac does not form carcinogen in users: USFDA

      Tests indicate heartburn drug Zantac does not form carcinogen in users: USFDA

      Medical Dialogues Bureau2 Nov 2019 9:30 AM IST
      Zantac sold over-the-counter in the United States by French drugmaker Sanofi SA, and some of its generic versions, have been recalled due to possible...
      Revenue from operations stood at Rs 2005 crore in Q2: Torrent Pharma

      Revenue from operations stood at Rs 2005 crore in Q2: Torrent Pharma

      Medical Dialogues Bureau2 Nov 2019 9:15 AM IST
      Consolidated revenue from operations stood at Rs 2,005 crore for the quarter under consideration as against Rs 1,894 crore for the same period last...
      Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial

      Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial

      Medical Dialogues Bureau2 Nov 2019 9:00 AM IST
      Out of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and...
      Landmark: Sanofi announces to reduce price of TB drug Rifapentine by 70 percent

      Landmark: Sanofi announces to reduce price of TB drug Rifapentine by 70 percent

      Medical Dialogues Bureau1 Nov 2019 3:29 PM IST
      Scale-up of affordable Rifapentine stands to benefit over a million people in India alone, where more people suffer from TB than anywhere else in the...
      Cadila Healthcare gets EIR from USFDA for Baddi facility

      Cadila Healthcare gets EIR from USFDA for Baddi facility

      Medical Dialogues Bureau1 Nov 2019 2:11 PM IST
      New Delhi: Drug firm Cadila Healthcare on Thursday said its Baddi facility in Himachal Pradesh has received establishment inspection report (EIR) from...
      Boehringer Ingelheim, The Defeat-NCD Partnership join hands to fight non-communicable diseases

      Boehringer Ingelheim, The Defeat-NCD Partnership join hands to fight non-communicable diseases

      Medical Dialogues Bureau1 Nov 2019 2:07 PM IST
      Germany – Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced today its partnership with The Defeat-NCD Partnership,...
      GSK Pharma reports Q2 profit at Rs 503 crore

      GSK Pharma reports Q2 profit at Rs 503 crore

      Medical Dialogues Bureau1 Nov 2019 9:15 AM IST
      GSK Pharmaceuticals continues to drive improved operational efficiencies reflecting in earnings before interest, tax, depreciation and amortisation...
      Bayer Roundup suits increase to 42700

      Bayer Roundup suits increase to 42700

      Medical Dialogues Bureau1 Nov 2019 9:00 AM IST
      A court-appointed mediator between Bayer and US plaintiffs in August denied reports the company had offered an $8 billion settlement to get the cases...
      SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

      SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

      Medical Dialogues Bureau31 Oct 2019 9:45 AM IST
      Novartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings...
      Biogen, Alkermes get USFDA nod for multiple sclerosis drug Vumerity

      Biogen, Alkermes get USFDA nod for multiple sclerosis drug Vumerity

      Medical Dialogues Bureau31 Oct 2019 9:25 AM IST
      The new drug, Vumerity, was approved to treat relapsing forms of multiple sclerosis, a disabling autoimmune disease that damages the central nervous...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok